We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+16.1%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.69B
AUM Growth
+$3.31M
Cap. Flow
-$44.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
77.31%
Holding
52
New
6
Increased
5
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$86.1M
2
ZYME icon
Zymeworks
ZYME
+$68M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23.6M
4
ALKS icon
Alkermes
ALKS
+$14.9M
5
VRNA
Verona Pharma
VRNA
+$14.8M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$143M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$82.5M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.1M
4
BEAM icon
Beam Therapeutics
BEAM
+$10.3M
5
DNA icon
Ginkgo Bioworks
DNA
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UPB
51
Upstream Bio Inc
UPB
$349M
– –
-60,000
Closed -$367K
KLRS
52
Kalaris Therapeutics
KLRS
$88.7M
– –
-201,718
Closed -$1.62M
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q2 2025 Portfolio in Review

As of Q2 2025, EcoR1 Capital held 52 positions worth $1.69B, up 0.2% from $1.69B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

EcoR1 Capital's Q2 2025 filing shows 6 new, 5 increased, 4 reduced and 15 closed positions. Its largest new stake was iTeos Therapeutics: 10,688,978 shares worth $107M. The largest sale was Prothena Corp, an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • EcoR1 Capital's largest Q2 2025 buy was iTeos Therapeutics: 10,688,978 shares worth $107M.
  • EcoR1 Capital added most to Zymeworks in Q2 2025, an estimated $68M increase.
  • EcoR1 Capital's biggest Q2 2025 reduction was Oric Pharmaceuticals, cutting an estimated $12.1M.
  • EcoR1 Capital fully exited Prothena Corp in Q2 2025, selling an estimated $143M.
  • EcoR1 Capital's ten largest holdings make up 77% of its $1.69B portfolio in Q2 2025.
  • EcoR1 Capital opened 6 new positions and closed 15 in Q2 2025.
  • EcoR1 Capital's portfolio value rose 0.2% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.